ClinicalTrials.gg
RecruitingNCT07945730SHEKANUpdated Nov 18, 2026

How a Ketogenic Diet Affects Hormones and Metabolism in Women

An interventional study of Ketogenic Diet in Menstrual Cycle and Premenopausal, sponsored by Ohio State University. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Ohio State University · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Feb 2026, registered Nov 2026).
  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

This study is looking at how a ketogenic diet (a way of eating that is high in fat and very low in carbohydrates) affects hormones, metabolism, and body composition in healthy women who have regular menstrual cycles. While ketogenic diets have become popular and have been studied in men and in people with certain health conditions, much less is known about how this way of eating affects the hormones and cycles of healthy, premenopausal women.

Researchers believe that a ketogenic diet may cause measurable changes in reproductive hormones (such as estrogen and progesterone), metabolic markers (like ketone and cholesterol levels), and body composition (such as body fat and lean muscle mass) across the menstrual cycle. The study will also explore whether the diet affects mood, sleep, and overall well-being.

Participants will follow a ketogenic diet for 12 weeks, roughly covering three menstrual cycles. During the first month, they will receive help with meal planning and food, and for the remaining weeks they will follow the diet on their own with continued support from a dietitian. Throughout the study, participants will check in weekly for blood draws, body composition scans, and a resting metabolism test, and will use at-home tools such as a smart ring and daily finger-stick tests to track their ketone levels and hormone patterns. Participants will also complete surveys about their mood, sleep, and general well-being.

By studying these changes closely, the research team hopes to better understand how a ketogenic diet affects women's health and hormones, which could help guide future dietary recommendations designed specifically for women.

Read the detailed description

etogenic diets induce a metabolic shift from glucose to fat as the primary energy substrate, resulting in nutritional ketosis and associated changes in insulin sensitivity, lipid profiles, and body composition. While ketogenic diets have been studied extensively in the context of epilepsy, obesity, type 2 diabetes, and neurodegenerative disease, most existing research either underrepresents women or fails to account for hormonal fluctuations across the menstrual cycle. Preliminary evidence suggests that sex hormones and substrate metabolism differ meaningfully between men and women in their response to dietary interventions, yet these differences remain poorly characterized during ketogenic adaptation, particularly in healthy, regularly menstruating women.

This pilot study is designed to characterize the physiological, hormonal, metabolic, and behavioral adaptations that occur during a 12-week, well-formulated ketogenic diet in healthy, premenopausal women, capturing data across approximately three consecutive menstrual cycles. The diet is structured in two phases: an initial 4-week period with controlled feeding support (grocery provision or meal delivery services matched to individual caloric needs), followed by 8 weeks of self-guided dietary adherence supported by ongoing dietitian consultation and educational materials. Dietary adherence and ketosis status (target: ≥0.5 mmol/L blood BHB) are monitored daily via at-home fingerstick testing.

Participants attend weekly in-person study visits for the duration of the 12-week intervention, during which fasting venous blood is drawn to assess reproductive hormone levels, resting metabolic rate is measured via indirect calorimetry, and body composition is tracked using bioelectrical impedance (InBody). Full-body DXA scans, which provide a more precise measure of fat mass, lean mass, and visceral adiposity, are performed only at baseline and at the final Week 16 visit, in order to limit participants' cumulative radiation exposure. Menstrual cycle phase and ovulatory status are tracked continuously using a wearable basal body temperature ring and urine-based hormone test strips, allowing the research team to align hormonal blood draws with specific points in each participant's cycle. Validated PROMIS instruments are used to assess mood, sleep quality, anxiety, depression, and cognitive function at scheduled intervals throughout the study.

As a pilot study, SHEKAN is designed primarily to assess feasibility and estimate effect sizes to inform the design of future, larger-scale investigations, rather than to test a specific hypothesis with adequate statistical power to detect small between-group differences. Findings are intended to help characterize sex-specific responses to ketogenic diets and inform future research and clinical guidance regarding women's metabolic and reproductive health during dietary intervention.

02

Conditions studied

  • Menstrual Cycle
  • Premenopausal

Keywords

  • Nutritional Ketosis
  • Ketogenic Diet
  • Menstrual Cycle
  • Body Composition
  • Reproductive Hormones
  • Beta-hydroxybutyrate
  • Resting metabolic rate
  • Premenopausal women
03

In context

Lead sponsor

Ohio State University is the lead sponsor of 664 studies on the registry; 149 are open to participants now.

Of its 67 completed or terminated interventional studies of FDA-regulated products, 49 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Women aged 18-40
  • Self-reported, 27-32 day menstrual cycles
  • Must have access to a smartphone, tablet or computer to access the diet survey and resources
  • Must be willing to self-report menstrual cycles

Exclusion criteria

Exclusion Criteria:

  • History of reproductive disorders
  • Pregnancy or lactation during the study period
  • Recurring disordered eating behaviors or other food security concerns
  • Suffered a lower body injury in the last 6 months
  • Other major health concerns
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Ketogenic Diet Intervention Group

    Healthy, premenopausal women (ages 18-40) with regular menstrual cycles will follow a 12-week well-formulated ketogenic diet designed to maintain nutritional ketosis (≥0.5 mmol/L BHB). During the first 4 weeks, participants receive controlled feeding support (grocery provision or meal delivery services). Weeks 5-12 transition to a self-guided ketogenic diet with continued dietitian support and educational resources. Participants undergo weekly in-person study visits (blood draws, resting metabolic rate testing, body composition scans, and validated surveys) plus daily at-home monitoring (fingerstick ketone/glucose testing, nightly wearable ring, and urine ovulation tracking) across approximately 16 weeks total, including baseline and final follow-up visits.

    Other: Ketogenic Diet

Interventions

  • OtherKetogenic Diet

    A high-fat, low-carbohydrate, moderate-protein diet intended to induce and maintain nutritional ketosis over 12 weeks, with an initial 4-week period of controlled feeding support followed by 8 weeks of self-guided adherence with dietitian consultation and educational materials.

06

What researchers measure

Primary outcomes

  1. Change in Ovulatory Status

    To evaluate whether ketogenic dietary intervention or exogenous ketone supplementation restores ovulatory function in women with Polycystic Ovary Syndrome (PCOS). Ovulatory status will be assessed using a combination of validated measures, including basal body temperature monitoring via BBT, urinary luteinizing hormone (LH) surge detection using ovulation predictor kits, and serum progesterone levels. Participants will be classified as ovulatory or anovulatory based on hormonal and temperature cycle confirmation.

    Time frame: Baseline to 12 weeks

Secondary outcomes

  1. Change in Serum Progesterone Concentration (ng/mL)

    To determine the effects of ketogenic diet and exogenous ketone supplementation on circulating reproductive hormone concentrations. Serum progesterone will be analyzed using standard immunoassay techniques (Quest Diagnostics panels and/or validated ELISA assays). Hormonal changes will be compared between baseline and post-intervention to assess improvements in reproductive axis regulation.

    Time frame: Baseline to 12 weeks

  2. Change in Serum Estradiol Concentration (pg/mL)

    To determine the effects of ketogenic diet and exogenous ketone supplementation on circulating reproductive hormone concentrations. Serum estradiol will be analyzed using commercially available immunoassay kits (Quest Diagnostics panels and/or validated ELISA assays). Hormonal changes will be compared between baseline and post-intervention to assess improvements in reproductive axis regulation.

    Time frame: Baseline to 12 weeks

  3. Change in Serum Luteinizing Hormone Concentration (mIU/mL)

    To determine the effects of ketogenic diet and exogenous ketone supplementation on circulating reproductive hormone concentrations. Serum luteinizing hormone (LH) will be analyzed using standard immunoassay techniques (Quest Diagnostics panels and/or validated ELISA assays). Hormonal changes will be compared between baseline and post-intervention to assess improvements in reproductive axis regulation.

    Time frame: Baseline to 12 weeks

  4. Change in Serum Follicle Stimulating Hormone Concentrations (mIU/mL)

    To determine the effects of ketogenic diet and exogenous ketone supplementation on circulating reproductive hormone concentrations. Serum follicle-stimulating hormone (FSH) will be analyzed using standard immunoassay techniques (Quest Diagnostics panels and/or validated ELISA assays). Hormonal changes will be compared between baseline and post-intervention to assess improvements in reproductive axis regulation.

    Time frame: Baseline to 12 weeks

  5. Change in Daily Fasting BHB (mmol/L)

    To assess changes in metabolic parameters including fasting β-hydroxybutyrate (BHB). Capillary ketones will be measured daily using KetoMojo handheld monitors.

    Time frame: Baseline to 12 weeks (Daily)

  6. Change in Daily Fasting Glucose (mg/dL)

    To assess changes in metabolic parameters including fasting glucose. Capillary glucose will be measured daily using KetoMojo handheld monitors.

    Time frame: Baseline to 12 weeks (Daily)

  7. Change in Serum Insulin Concentration (µIU/mL)

    To assess the effect of ketogenic diet and exogenous ketone supplementation on fasting insulin levels. Serum insulin will be measured at laboratory visits via immunoassay (Quest Diagnostics or validated ELISA). Mean change from baseline will be compared across groups.

    Time frame: Baseline to 12 weeks

  8. Change in Serum Total Cholesterol Concentration (mg/dL)

    To assess changes in fasting serum total cholesterol in response to ketogenic diet and exogenous ketone supplementation. Blood samples will be collected biweekly and analyzed using standard clinical chemistry methods (Quest Diagnostics). Mean change from baseline to 12 weeks will be reported.

    Time frame: Baseline to 12 weeks

  9. Change in Serum Triglyceride Concentration (mg/dL)

    To determine the effect of ketogenic diet and exogenous ketone supplementation on fasting triglyceride concentrations. Serum triglycerides will be measured via standard lipid panel. Mean change from baseline to 12 weeks will be compared across groups.

    Time frame: Baseline to 12 weeks

  10. Change in Serum LDL Cholesterol Concentration (mg/dL)

    To assess the effect of ketogenic diet and exogenous ketone supplementation on fasting low-density lipoprotein (LDL) cholesterol. Serum LDL will be measured via standard lipid panel (Quest Diagnostics). Mean change from baseline to post-intervention will be reported.

    Time frame: Baseline to 12 weeks

  11. Change in Serum HDL Cholesterol Concentration (mg/dL)

    To evaluate changes in fasting high-density lipoprotein (HDL) cholesterol following ketogenic diet or exogenous ketone supplementation. Serum HDL will be analyzed by clinical chemistry methods. Mean change from baseline to 12 weeks will be reported.

    Time frame: Baseline to 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Physical Activity and Educational Services Building
    Columbus, Ohio 43210, United States
    Recruiting
    • Program Manager Department of Human Sciences - Kinesiology · Contactroe.236@osu.edu · 6142470287
    • Madison Kackley, PhD, Kinesiology · Principal investigator
08

References and documents

Publications

  • Sadoyama T, Masuda T, Miyano H. Relationships between muscle fibre conduction velocity and frequency parameters of surface EMG during sustained contraction. European Journal of Applied Physiology and Occupational Physiology. 1983;51(2):247-256. doi:10.1007/BF00455188
  • De Luca CJ. The Use of Surface Electromyography in Biomechanics. Journal of Applied Biomechanics. 1997;13(2):135-163. doi:10.1123/jab.13.2.135.
  • Bambaeichi E, Reilly T, Cable NT, Giacomoni M. The isolated and combined effects of menstrual cycle phase and time-of-day on muscle strength of eumenorrheic females. Chronobiol Int. 2004 Jul;21(4-5):645-60. doi: 10.1081/cbi-120039206. PubMed 15470960 ↗
  • Thompson BM, Drover KB, Stellmaker RJ, Sculley DV, Janse de Jonge XAK. The Effect of the Menstrual Cycle and Oral Contraceptive Cycle on Muscle Performance and Perceptual Measures. Int J Environ Res Public Health. 2021 Oct 9;18(20):10565. doi: 10.3390/ijerph182010565. PubMed 34682310 ↗
  • Pereira HM, Larson RD, Bemben DA. Menstrual Cycle Effects on Exercise-Induced Fatigability. Front Physiol. 2020 Jun 26;11:517. doi: 10.3389/fphys.2020.00517. eCollection 2020. PubMed 32670076 ↗
  • Tenan MS, Hackney AC, Griffin L. Maximal force and tremor changes across the menstrual cycle. Eur J Appl Physiol. 2016 Jan;116(1):153-60. doi: 10.1007/s00421-015-3258-x. Epub 2015 Sep 13. PubMed 26365403 ↗
  • Bouchard TP, Fehring RJ, Mu Q. Quantitative versus qualitative estrogen and luteinizing hormone testing for personal fertility monitoring. Expert Rev Mol Diagn. 2021 Dec;21(12):1349-1360. doi: 10.1080/14737159.2021.2000393. Epub 2021 Dec 3. PubMed 34714210 ↗
  • Papaioannou S, Aslam M, Al Wattar BH, Milnes RC, Knowles TG. User's acceptability of OvuSense: a novel vaginal temperature sensor for prediction of the fertile period. J Obstet Gynaecol. 2013 Oct;33(7):705-9. doi: 10.3109/01443615.2013.817984. PubMed 24127960 ↗
  • Thiyagarajan DK, Basit H, Jeanmonod R. Physiology, Menstrual Cycle. 2024 Sep 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK500020/ PubMed 29763196 ↗
  • Li D, Zhang L, Wang X. The Effect of Menstrual Cycle Phases on Approach-Avoidance Behaviors in Women: Evidence from Conscious and Unconscious Processes. Brain Sci. 2022 Oct 21;12(10):1417. doi: 10.3390/brainsci12101417. PubMed 36291350 ↗
  • Corbie-Smith GM, Durant RW, St George DM. Investigators' assessment of NIH mandated inclusion of women and minorities in research. Contemp Clin Trials. 2006 Dec;27(6):571-9. doi: 10.1016/j.cct.2006.05.012. Epub 2006 Jul 13. PubMed 16843069 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Deidentified datasets (no direct identifiers; no genetic/genomic data, as none will be generated for this study)

Supporting information: Study protocol, Statistical analysis plan

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Aug 2028, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2026
First posted
Nov 18, 2026
StartActual
Feb 6, 2026
Primary completionEst.
Aug 2028
CompletionEst.
Dec 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945730
Responsible party
Madison Kackley (Assistant Professor, Ohio State University) — Principal investigator
First posted
Nov 18, 2026
Start date
Feb 6, 2026
Primary completion
Aug 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion